Sharemaestro Newsreel

Novocure Ltd (NVCR) Stock Analysis & Forecast

Novocure Ltd (NVCR) saw its stock surge to $19.91 following stronger-than-expected Q2 2026 earnings. The company reported revenue that exceeded consensus estimates, growing 8.6% year-over-year. This recovery is primarily attributed to the FDA approval and multi-indication expansion of its Optune Pax treatment, especially after …

Treace Medical Concepts: Q2 Earnings Snapshot

Treace Medical Concepts Inc. (TMCI) reported a second-quarter loss of $15.9 million, equating to 24 cents per share. The orthopedic medical device maker generated $45.4 million in revenue for the period and expects full-year revenue to be between $204 million and $212 million. This …

Koninklijke Philips N.V. $PHG Position Raised by Royal Bank of Canada

Royal Bank of Canada increased its stake in Koninklijke Philips N.V. (PHG) by 13.1% in the first quarter, now holding shares valued at approximately $13.6 million. Despite institutional interest, analyst sentiment remains cautious, with a consensus "Reduce" rating for the stock. Philips recently exceeded …

Royal Bank of Canada Decreases Holdings in Penumbra, Inc. $PEN

Royal Bank of Canada significantly reduced its stake in Penumbra, Inc. by nearly 50% in the first quarter, selling 39,656 shares and retaining 39,794 shares valued at $13.1 million. This comes as Penumbra reported mixed financial results, with revenue slightly above estimates but EPS …

Globus Medical (NYSE:GMED): A Compelling Affordable Growth Opportunity

Co-Diagnostics Submits Co-Dx PCR Flu A/B & RSV Test for FDA Clearance

Co-Diagnostics has submitted its Co-Dx PCR Flu A/B & RSV multiplex respiratory test for FDA clearance, including a dual 510(k) premarket notification and a CLIA Waiver by Application. This submission is backed by extensive clinical studies involving over 1,400 patients and an analytical program …

Alamar Biosciences Inc expected to post a loss of 33 cents a share - Earnings Preview

Alamar Biosciences Inc is projected to report a loss of 33 cents per share, according to this earnings preview. The article, sourced from Reuters via Refinitiv, provides an outlook on the company's upcoming financial performance.

NeuroPace, Inc. expected to post a loss of 21 cents a share - Earnings Preview

NeuroPace, Inc. is projected to report a loss of 21 cents per share, according to this earnings preview. The article indicates that this financial outlook is based on information from Refinitiv. Full article access requires a TradingView subscription.

Butterfly Network (BFLY) Is Up 24.2% After Raising 2026 Guidance And Narrowing Losses - Has The Bull Case Changed?

SINTX Technologies Inc (SINT) Stock News Today

This page from TradingKey provides current stock news for SINTX Technologies Inc (SINT). It displays the latest stock price, market cap, and offers links to detailed financial information, stock scores, technical analysis, and ownership data. The article notes that more news is coming soon …

Czech National Bank Acquires 16,292 Shares of Medtronic PLC $MDT

The Czech National Bank increased its stake in Medtronic PLC (NYSE:MDT) by 4.7% in the second quarter, purchasing an additional 16,292 shares, bringing its total holdings to 365,443 shares valued at approximately $28.6 million. Medtronic recently exceeded quarterly earnings expectations, reporting $1.55 in adjusted …

Beacon Investment Advisory Services Inc. Has $9.03 Million Stock Holdings in Insulet Corporation $PODD

Beacon Investment Advisory Services Inc. reduced its stake in Insulet Corporation (NASDAQ:PODD) by 13.3% in the second quarter, now holding 59,333 shares valued at approximately $9.03 million. Despite Insulet reporting strong second-quarter revenues and adjusted EPS that beat analyst expectations, the company lowered its …

Levi & Korsinsky Notifies RxSight, Inc. (RXST) Investors - Lead Plaintiff Deadline on September 22, 2025

Levi & Korsinsky LLP has announced a lead plaintiff deadline of September 22, 2025, for investors of RxSight, Inc. (RXST) who suffered losses. The class action securities lawsuit alleges that RxSight made false statements regarding "adoption challenges," overstated product demand, and was unlikely to …

CVRx, Inc. (NASDAQ:CVRX) Given Consensus Recommendation of "Hold" by Brokerages

CVRx, Inc. (NASDAQ:CVRX) has received a consensus "Hold" recommendation from six brokerages, with an average 12-month price target of $6.90. The company's stock recently fell significantly to $2.72 after reporting a $0.53-per-share quarterly loss and negative net margin, despite beating revenue expectations. Analysts have …

Lumexa Imaging (NASDAQ:LMRI) Stock Rating Lowered by Wall Street Zen

Wall Street Zen has downgraded Lumexa Imaging (NASDAQ:LMRI) from a "buy" to a "hold" rating, despite the broader analyst consensus remaining a "Moderate Buy" with a $16.00 price target. Lumexa shares opened at $11.58, and institutional investors like BlackRock Inc. have recently increased their …

QT Imaging Holdings Inc (QTI) Stock News Today

This article provides an overview of QT Imaging Holdings Inc (QTI) stock news. It states that more news is coming soon, and highlights current stock information including its price, market cap, and links to various financial data sections on the TradingKey platform.

CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update

CytoSorbents Corporation reported its Q2 2026 financial results, with revenue unchanged at $9.6 million but an improved gross margin of 73%. The company reduced its operating loss by 27% and adjusted EBITDA loss by 38%, aiming for operating cash flow breakeven in the second …

Haemonetics (NYSE:HAE) Upgraded by Wall Street Zen to Strong-Buy Rating

Wall Street Zen has upgraded Haemonetics (NYSE:HAE) to a "strong-buy" rating, reflecting positive analyst sentiment and strong financial performance. The company exceeded quarterly expectations with $1.14 EPS and $339.38 million in revenue, leading management to raise its fiscal 2027 revenue-growth outlook to 5%-8%. Haemonetics' …

UBS Maintains Steris PLC(STE.US) With Buy Rating, Cuts Target Price to $270

UBS has reiterated its Buy rating for Steris PLC (STE.US) but has reduced the target price for the company's stock to $270. This adjustment reflects a continued positive outlook on Steris PLC despite a revised valuation.

Inogen Inc Q2 2026: Revenue $95.08M, EPS $(0.14) — 10-Q Summary

Inogen Inc. reported Q2 2026 revenue of $95.08M and diluted EPS of $(0.14), marking modest top-line growth and improved margins. The company's net loss narrowed to $3.85M from $4.15M a year prior, driven by higher unit volumes and favorable foreign exchange, particularly in international …

Icecure Medical Ltd (ICCM) News, Articles, Events & Latest Updates

IceCure Medical (ICCM) is actively expanding its clinical studies and commercial reach for its ProSense cryoablation technology. The company recently added Adventist Health as a U.S. clinical site for its "ChoICE" study for low-risk breast cancer and will report its first-half 2026 financial results …

Dimensional Fund Advisors LP Reduces Holdings in Varex Imaging $VREX

Sight Sciences (SGHT) Q2 2026 Earnings: Narrower Loss Drives 5.36% Stock Rally - Earnings Forecast Report

Sera Prognostics Q1 2026 Earnings: In-Line Loss of -$0.17 Per Share as Shares Advance 3.5% - Pre-Announcement Alert

MaxCyte (MXCT) Q1 2026 Earnings: Narrower Loss Beats Estimates as Shares Rise 6.31% - Segment Revenue Breakdown

MaxCyte, Inc. (MXCT) reported a Q2 loss of $0.08 per share, exceeding the Zacks Consensus Estimate of a $0.12 loss, and surpassed revenue estimates with $7.27 million. Despite beating earnings and revenue expectations in some recent quarters, the stock has underperformed the market this …

ADGM Q1 2026 Earnings: Wider-Than-Expected Loss Sends Shares Down 6.69% - Guidance Downgrade Alert

TELA Bio Q1 2026 Earnings: Wider Loss Highlights Cost Pressures - Forward EPS Estimate

iRhythm (IRTC) Stock Ignores Record Margins And Free Cash Flow

FEED Q1 2026 Earnings: Reported Loss of $6.88 Per Share Amid Minimal Disclosure - Revenue Report

NVNO Q2 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Development Costs - EPS Consistency Score

CVRx (CVRX) Stock Reels From Guidance Cut And Cash Burn Fears

CVRx (CVRX) stock dropped almost 60% after cutting its 2026 revenue guidance to US$58m-US$60m and providing softer Q3 guidance. Despite strong Q2 revenue of US$15.7m and high gross margins of 87%, the company reported a US$14.0m net loss and continues to burn cash, raising …

Inogen (INGN) Stock Drops As Guidance Cut Clouds Margin Progress

Haemonetics (HAE) Stock Extends Run As Cash Flow Strength Meets Margin Pressure

QuidelOrtho (QDEL) Stock Sinks As Cash Burn And Debt Eclipse Progress

Cerus Corporation 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:CERS) 2026-08-08

Elutia Inc. (ELUT) Files Form 8-K: Nasdaq-Listed Delaware Biologics Company Updates Corporate Information

Elutia, Inc. (ELUT) has filed a Form 8-K disclosing that it received a notice from Nasdaq regarding non-compliance with the minimum bid price requirement. This places the company's Nasdaq listing at risk, and it must regain compliance within a defined period to avoid delisting. …